If you work in medical device marketing, you need to understand one fundamental concept that governs everything you do: labeling. Not the sticker on the box -- the legal definition of labeling that the FDA uses, which is far broader than most marketers realize. In the FDA's world, your brochure is labeling. Your website is labeling. Your sales presentation is labeling. And every piece of labeling must comply with the same federal regulations that govern the instructions for use that ship inside the product packaging.

After 18 years helping medical device companies navigate the relationship between labeling and marketing, I have seen how misunderstanding this connection creates serious compliance risk. Companies that treat marketing as separate from labeling inevitably cross lines they did not know existed. In this article, I am going to explain exactly how the FDA defines labeling, why it matters for your marketing strategy, and how to align your promotional activities with your labeling to create a marketing program that is both effective and compliant.

The FDA Definition of Labeling: Much Broader Than You Think

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines labeling in Section 201(m) as "all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article." The Supreme Court, in Kordel v. United States (1948), interpreted "accompanying" to include any materials that supplement or explain the article, even if they are not physically attached to it.

This interpretation means that the following are all considered "labeling" under federal law:

The FDA distinguishes between two types of labeling that are relevant to marketing: the "label" (information physically on the device or its immediate container) and "labeling" (everything else that accompanies or supplements the device). Promotional materials fall into the broader "labeling" category, which is why the FDA has jurisdiction over your marketing.

The Relationship Between Approved Labeling and Marketing Claims

Your FDA-cleared or approved labeling -- particularly your indications for use statement and your intended use -- establishes the boundaries of your marketing. This relationship is absolute and non-negotiable.

Here is how it works in practice:

Indications for Use

Your indications for use statement defines what your device is intended to do, who it is intended for, and under what conditions it should be used. Every marketing claim you make must fall within these boundaries. If your indications statement says your device is intended for use by trained surgeons in hospital settings, you cannot market it for use by non-surgeon practitioners in ambulatory surgery centers unless your clearance covers that use.

Intended Use

The intended use is broader than the indications for use and describes the general purpose of the device. The FDA has stated that intended use can be determined not just by what you say in your submission, but by how you market the device. This is the critical connection: your marketing can actually change the FDA's interpretation of your intended use, potentially making your device a new, unapproved device.

Contraindications and Warnings

Your labeling includes specific contraindications, warnings, and precautions. Your marketing must not minimize, omit, or contradict this safety information. The fair balance requirement means that your promotional materials must present risk information alongside benefit claims.

Critical Concept: The FDA views your marketing as an expression of your device's intended use. If your marketing suggests uses, populations, or applications that are not covered by your cleared labeling, the FDA can determine that you are marketing a "new device" that requires its own clearance or approval. This is not a minor compliance issue -- it is a fundamental regulatory violation that can result in your device being deemed adulterated or misbranded.

When Marketing Becomes Labeling: The Legal Tests

Courts have established several tests for determining when a marketing material is considered labeling under the FD&C Act:

The "Textual Relationship" Test

Materials have a textual relationship with the device when they reference the device by name, discuss its use, or describe its performance. Most marketing materials pass this test easily -- the whole point of marketing is to discuss your device.

The "Integral Part" Test

Materials are labeling if they are an integral part of the distribution and sale of the device. Sales brochures, product websites, and sales presentations all qualify because they are directly connected to the commercial distribution of the device.

The "Designed for Use" Test

If a material is designed to be used with the device or to promote the sale or use of the device, it is labeling. This captures virtually all marketing materials, since they are, by definition, designed to promote sales.

The practical takeaway is simple: if you create it to promote or support the use of your device, it is labeling. Do not try to argue that your sales brochure is not labeling. It is. And it must comply with labeling regulations.

Misbranding: The Regulatory Consequence of Labeling Violations

When your marketing (labeling) does not comply with FDA requirements, your device is considered "misbranded" under the FD&C Act. Misbranding is a federal violation with serious consequences.

A device is misbranded if:

The consequences of marketing a misbranded device include FDA enforcement actions ranging from warning letters to product seizures, injunctions, and criminal prosecution. For marketing professionals, understanding that non-compliant marketing creates a misbranded device -- not just a compliance issue -- reframes the stakes entirely.

The 510(k) Labeling Connection

For devices cleared through the 510(k) process, the connection between labeling and marketing is particularly important. Your 510(k) submission includes proposed labeling -- including your indications for use, intended use, and safety information -- that the FDA reviews as part of the clearance decision.

Key implications for marketing:

PMA Devices: Stricter Labeling Requirements

Devices that require Premarket Approval (PMA) face even stricter labeling requirements. PMA labeling is specifically approved by the FDA, and deviations from the approved labeling in marketing materials are serious violations.

For PMA devices:

Practical Distinction: For 510(k) devices, the FDA reviews labeling as part of the clearance process but does not pre-approve marketing materials. For PMA devices, the FDA has greater authority to review and approve promotional materials. But for both pathways, the principle is the same: your marketing must align with your cleared or approved labeling.

How to Align Your Marketing with Your Labeling

Building alignment between labeling and marketing is not a one-time exercise -- it is an ongoing discipline. Here is the framework I use with clients:

Step 1: Know Your Labeling Inside and Out

Your marketing team must have a thorough understanding of your device's labeling -- not just the indications for use, but the complete labeling package: IFU, warnings, contraindications, precautions, and performance data. I am consistently surprised by how many marketing professionals have never read the complete IFU for the device they are marketing. This is the foundation document for everything you can and cannot say.

Step 2: Create a Claims Map

Map every marketing claim you want to make to a specific section of your labeling. If a claim cannot be traced to your labeling, it either needs labeling support (which may require a regulatory submission) or it cannot be made. This claims map becomes your planning tool for marketing strategy and your compliance reference for material development.

Step 3: Review Marketing Against Labeling

Every marketing material should be reviewed against your labeling as part of the promotional review process. The reviewer should verify that all claims are within indications, that safety information is consistent with the labeling, and that the overall impression of the marketing material aligns with what the labeling supports.

Step 4: Update Marketing When Labeling Changes

When your labeling changes -- whether through a new 510(k), a PMA supplement, or a labeling update -- your marketing must be updated to reflect those changes. This includes adding new indications, incorporating new warnings, and updating performance data. Maintaining outdated marketing after a labeling change is a compliance risk.

Step 5: Coordinate Labeling and Marketing Strategy

The most sophisticated device companies coordinate their labeling and marketing strategies proactively. If the marketing team identifies a high-value claim that is not currently supported by the labeling, they work with the regulatory team to determine whether a labeling update is feasible and what evidence would be required. This proactive approach turns labeling from a constraint into a strategic tool.

Common Labeling-Marketing Misalignments

Here are the most common ways I see marketing materials drift out of alignment with labeling:

Digital Labeling and Electronic IFUs

The shift toward digital labeling -- electronic IFUs (eIFUs), QR codes linking to labeling information, and online labeling repositories -- has implications for marketing as well.

The FDA has issued guidance on the use of electronic labeling for medical devices (21 CFR 801.128 for prescription devices), allowing manufacturers to provide labeling electronically in certain circumstances. This creates opportunities for more dynamic labeling that can be updated more easily and linked directly to marketing materials.

For marketers, digital labeling means:

However, digital labeling also creates risks. If your labeling is updated but the link in your marketing materials still points to the old version, you have a compliance problem. Implement a system for tracking labeling versions and updating marketing links when labeling changes.

Labeling for Combination Products

Combination products -- devices combined with drugs or biologics -- face unique labeling requirements that affect marketing in complex ways.

The lead regulatory center (CDRH, CDER, or CBER) determines the primary regulatory pathway, but the labeling must address both the device and the drug/biologic components. Marketing for combination products must:

This complexity makes marketing combination products particularly challenging. I recommend that companies marketing combination products have their promotional materials reviewed by regulatory specialists with expertise in both device and drug/biologic regulations.

International Labeling Differences

If you market your device internationally, you need to understand that labeling requirements vary significantly across jurisdictions, and these differences affect what you can say in each market.

For companies marketing globally, I recommend maintaining a labeling matrix that tracks the labeling requirements and marketing claims allowed in each market. This prevents the common mistake of using US marketing materials in markets where the claims are not supported by the local regulatory approval.

Key Takeaway: Your labeling is not just a regulatory document that sits in a filing cabinet -- it is the foundational document that defines what your marketing can say, who it can target, and what claims it can make. Every marketing professional in your organization should be as familiar with your labeling as your regulatory team is. When labeling and marketing are aligned, you have a powerful, compliant marketing program. When they diverge, you have a misbranded device and a regulatory problem.

Labeling Updates as Marketing Opportunities

Most device companies view labeling updates as regulatory chores. The savviest companies view them as marketing opportunities. Here is how:

The companies that treat labeling and marketing as an integrated strategy -- not as separate functions -- are the ones that consistently outperform their competitors. Your regulatory submissions and your marketing plans should be developed in coordination, with each informing the other.

Practical Recommendations for Marketing Teams

I want to close with practical advice for marketing professionals working in medical device companies:

The relationship between labeling and marketing is the most fundamental compliance relationship in medical device marketing. Master it, and you build a marketing program on a solid regulatory foundation. Ignore it, and you build on sand.

Labeling in the Age of Software and SaMD

Software as a Medical Device (SaMD) and devices with embedded software present new labeling challenges that directly affect marketing. The FDA has been developing frameworks for SaMD regulation, and the labeling requirements for these devices differ from traditional hardware devices in important ways.

For software-based devices, labeling considerations include:

As the medical device industry continues its digital transformation, the relationship between labeling and marketing will become more complex, not less. Companies that build robust processes for managing this relationship now will have a significant advantage as the regulatory landscape continues to evolve.

Labeling Audits: Ensuring Ongoing Alignment

Given how critical the labeling-marketing relationship is, I recommend that every medical device company conduct periodic labeling alignment audits. Here is how to structure them:

The labeling alignment audit is not glamorous work, but it is some of the most important work your regulatory and marketing teams can do together. It catches the gradual drift that occurs as labeling evolves, marketing campaigns change, and institutional knowledge turns over. Companies that conduct regular audits rarely face labeling-related enforcement actions. Companies that skip them are playing regulatory roulette.